References
- BAILLIE, T. A., 1988, Metabolic activation of valproic acid and drug-mediated hepatotoxicity. Role of the terminal olefin, 2-n-propy1-4-pentenoic acid. Chemical Research Toxicology, 1, 195–199.
- BAILLIE, T. A. and SHEFFELS, P. A., 1995, Valproic acid: chemistry and biotransformation. In R. H. Levey, R. H. Mattson and B. S. Meldrum (eds), Antiepileptic Drugs (New York: Raven), pp. 589–604.
- CHILCOTT, J., TAPPENDEN, P., JONES, M. L. and WIGHT, J. P., 2001, A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. Clinical Therapy, 23, 1792–1823.
- ECKLAND, D. A. and DANHOF, M., 2000, Clinical pharmacokinetics of pioglitazone. Experimental Clinical Endocrinology Diabetes, 108 (Suppl. 2), S234—S242.
- EPIFANIO, R., CAMARGO, W. and PINTO, A. C., 1988, Oxidative cleavage of 1,2-glycols and a-hydroxy ketones with the Jones reagent. Tetrahedron Letters, 29, 6403–6406.
- EVANS, P. A., ROSEMAN, J. D. and GARBER, L. T., 1996, Direct oxidation of primary tert-butyldimethylsily1 ethers to carboxylic acids with Jones reagent. Synthetic Communications, 26, 4685–4692.
- FIESER, M. and FIESER, L. F., 1967, Reagents for Organic Synthesis (New York: Wiley).
- HANEFELD, M., 2001, Pharmacokinetics and clinical efficacy of pioglitazone. UCP Supplement 12, September, 19–25.
- KASSAHUN, K., PEARSON, P. G., TANG, W., MCINTOSH, I., LEUNG, K., ELMORE, C., DEAN, D., WANG, R., Doss, G. and BAILLIE, T., 2001, Studies on the metabolism of troglitazone to reactive intermediate in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission. Chemical Research Toxicology, 14, 62–70.
- KIYOTA, Y., KONDO, T., MAESHIBA, Y., HASHIMOTO, A., YAMSHITA, K., YOSHIMURA, Y., MOTOHASHI, M. and TANAYAMA, S., 1997, Studies on the metabolism of the new antidiabetic agent pioglitazone. Identification of metabolites in rats and dogs. Arzneim-Forschl Drug Research, 47, 22–28.
- KRIETER, P. A., COLLETTI, A., Doss, G. and MILLE R., 1994, Disposition and metabolism of the hypoglycemic agent pioglitazone in rats. Drug Metabolism and Disposition, 22, 625–630.
- MAESHIBA, Y., YUTAKA, K., YAMASHITA, K., YOSHINOBU, Y., MOTOHASHI, M. and TANAYAMA, S., 1997, Disposition of the new antidiabetic agent pioglitazone in rats, dogs and monkeys. Arzneim-ForschlDrug Research, 47, 29–35.
- MUDALIAR, S. and HENRY, R. R., 2001, New oral therapies for type 2 diabetes mellitus: the glitazone or insulin sensitizers. Annual Review of Medicine, 52, 239–257.
- SHINSEISHIRYO GAIYO, THE, 2000, Medical review for pioglitazone in support of an indication for diabetes. Obtained through Freedom of Information from the Ministry of Health, Labor and Welfare, MHLW (Koseirodosho), Japan.
- SMITH, P. K., KROHN, R. I., HERMANSON, G. T., MALLIA, A. K., GARTNER, F. H., PROVERNZANO, M. D., FUJIMOTO, E. K., GOEKE, N. M., OLSON, B. J. and KLENK, D. C., 1985, Measurement of protein using bicinchoninic acid. Analytical Biochemistry, 150, 76–85.
- SOHDA, T., IKEDA, H. and MEGURO, K., 1995, Studies on antidiabetic agents. XII. Synthesis and activity of the metabolites of (±)-5-[p-[2-(5-ethy1-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione-(pioglitazone). Chemical and Pharmaceutical Bulletin, 43, 2168–2172.
- SOOD, V., COLLERAN, K. and BURGE, M. R., 2000, Thiazolidinediones: a comparative review of approved uses. Diabetes Technology Therapy, 2, 429–440.
- TANIS, S., PARKER, T., COLCA, J. R., MISHER, R. M. and KLETZEIN, R. F., 1996, Synthesis and biological activity of metabolites of the antidiabetic, antihyperglycemic agent pioglitazone. Journal of Medicinal Chemistry, 39, 5053–5063.
- ZHONG, W. Z. and LAKINGS, D. B., 1989, Determination of pioglitazone in dog serum using solid phase extraction and high performance liquid chromatography with ultraviolet (229 nm) detection. Journal of Chromatography, 490, 377–385.